| Objective:Epithelial ovarian cancer is the most common malignant tumor of the female reproductive system, and its mortality rate Cancer still the first female reproductive system. One of serous ovarian cancer is epithelial ovarian cancer the most common histological type, accounting for 50% of malignant ovarian tumors. World Health Organization (WHO) the biological behavior of their further classified as benign, malignant and intermediate type that is at the junction. Serous ovarian cancer early diagnosis, prognosis and clinical treatment of serous ovarian cancer are the main coreProto-oncogene activation, tumor suppressor gene loss of function as well as some modification of gene function lead to changes in tumor occurrence and development. Research on tumor suppressor genes in epithelial ovrian cancer research has become a hot field. This article will research ARHI, PTEN, WWOX tumor suppressor gene for serous ovarian c ancer.ARHI, PTEN, WWOX scholars in recent years are found in tumor suppressor genes, respectively, in normal tissue( breast, lung, intestinal, etc.)to detect the expression of their normal, tumor tissue is also found decreased expression or missing, was particularly prevalent in the breast cancer, lung cancer, colorectal cancer, etc.In this paper, through the application of reverse transcription - polymerase chain reaction(RT-PCR)used to detect the source of the normal epithelial ovarian tissue, benign ovarian serous cystadenoma, borderline ovarian serous cystadenoma, serous ovarian cancer tissue ARHI, PTEN WWOX gene and expression of its serous ovarian cancer occurrence and the evolution of the relevant pathological mechanism and their clinical significance.Methed:Using reverse transcription - polymerase chain reaction (RT-PCR) used to detect the source of 10 cases of normal ovarian epithelium, 10 cases of benign ovarian serous cystadenoma, 12 cases of borderline ovarian serous cystadenoma, 45 cases of serous ovarian cancer in ARHI, PTEN gene expression and WWOX, and three markers associated with the clinicopathological characteristics of the comparative analysis. In serous ovarian cancer,â… period of four cases,â…¡period of 12 cases,â…¢period of 21 cases,â…£period eight cases; G1 Example 5 class, G2 class in 15 cases, G3 class 25 cases; there is greater omentum and lymph node metastasis 30 cases, no omental and lymph node metastasis in 15 cases.Results: 1 ARHI in normal ovary, benign ovarian serous cystadenoma, borderline ovarian serous cystadenoma, serous ovarian cancer in the positive expression rates were 100%(10/10),70%(7/10), 67%(8/12), 22%(10/45). The positive expression rate of ARHI in serous ovarian cancer than normal ovary, benign ovarian serous cystadenoma, borderline ovarian serous cystadenoma, the difference has statistical significance(P <0.01,P<0.01,P<0.01);ARHI in normal ovarian and borderline ovarian serous cystadenoma, a benign ovarian serous cystadenoma and borderline ovarian serous cystadenoma has no statistically significant differences in expression(P>0.01).2 PTEN in normal ovary, benign ovarian serous cystadenoma, borderline ovarian serous cystadenoma, serous ovarian cancer in the positive expression rates were 100%(10/10),100%(10/10),92%(11/12),51%(23/45).The positive expression rate of PTEN in serous ovarian cancer than normal ovary, benign ovarian serous cystadenoma, the difference has statistical significance(P<0.01, P<0.01). PTEN in normal ovarian and borderline ovarian serous cystadenoma, a benign ovarian serous cystadenoma and borderline ovarian serous cystadenoma,borderline ovarian serous cystadenoma and seous ovarian cancer has no statistically significant differences in expression(P>0.01).3 WWOX in normal ovary, benign ovarian serous cystadenoma, borderline ovarian serous cystadenoma, serous ovarian cancer in the positive expression rates were 100%(10/10),90%(9/10),83%(10/12),40%(18/45).The positive expression rate of WWOX in serous ovarian cancer than normal ovary, benign ovarian serous cystadenoma, the difference has statistical significance(P<0.01,P<0.01).WWOX in normal ovarian and borderline ovarian serous cystadenoma, a benign ovarian serous cystadenoma and borderline ovarian serous cystadenoma, borderline ovarian serous cystadenoma and seous ovarian cancer has no statistically significant differences in expression(P>0.01).4 The relationship of between ARHI, PTEN and WWOX expression and the clinicopathological features in serous ovarian cancer High - in the differentiation group and the poorly differentiated group: ARHI in ovarian serous carcinoma - poorly differentiated in the differentiation group and positive group were 30%(6/20), 16%(4/25), two groups There was no significant difference(P>0.05); PTEN serous ovarian cancer at a high - and poorly differentiated in the differentiation of the positive group were 75%(15/20), 32%(8/ 25), difference between two groups There was a significant (P <0.05); WWOX serous ovarian cancer at a high - and poorly differentiated in the differentiation of the positive group were 55%(11/20), 28%(7/25), no difference between the two groups significant(P>0.05).â… -â…¡Phaseâ…¢-â…£compare: ARHI in serous ovarian cancerâ… -â…¡period andâ…¢-â…£a view of the positive group were 44%(7/16), 10%(3/29), the two group there was a significant difference (P<0.05); PTEN in serous ovarian cancerâ… -â…¡period andâ…¢-â…£a view of the positive group were 81% (13/16), 34%(10/29), difference between the two groups was significant(P<0.05); WWOX in serous ovarian cancerâ… -â…¡period andâ…¢-â…£a view of the positive group were 63% (10/16), 28%(8/29) , there is difference between two groups was significant(P<0.05). ARHI in omental and lymph node metastasis group and no greater omentum and lymph node metastasis, respectively, the positive rate of 7%(2/30), 53%(8/ 15), there is difference between two groups was significant (P< 0.05); PTEN in omental and lymph node metastasis group and no greater omentum and lymph node-positive group were 37% (11/30), 80%(12/15), there is difference between two groups was significant (P<0.05); WWOX in omental and lymph node metastasis group and no greater omentum and lymph node-positive group were 27%(8/30), 67%(10/15), difference between two groups There was a significant (P<0.05).5 ARHI and PTEN in ovarian serous carcinoma was positively correlated (r3=0.587,P<0.05).ARHI and WWOX in ovarian serous carcinoma was positively correlated(r3=0.587,P<0.05). PTEN and WWOX in ovarian serous carcinoma was positively correlated (r3=0.587,P<0.05).Conclusions:1 At the level of this experiment showed that gene ARHI, PTEN and WWOX serous ovarian cancer at the positive expression was significantly lower than the normal ovary, benign ovarian serous cystadenoma confirmed ARHI, PTEN and WWOX involved in serous ovarian cancer occurrence and development of , and the deterioration of the transfer process.2 This experiment shows that at the level of gene ARHI, PTEN and WWOX in ovarian serous carcinoma and stage and lymph node metastasis greater omentum and the negative correlation, confirmed the ARHI, PTEN and WWOX in ovarian serous early diagnosis of cancer, serous ovarian cancer to determine the degree of malignancy of the Medium play an important role.3 This experiment showed that the level of the gene ARHI, PTEN and WWOX in ovarian serous carcinoma associated, suggesting that ARHI, PTEN and WWOX involved in serous ovarian cancer development, transfer and deterioration.4 The topic for serous ovarian cancer gene therapy provides a theoretical foundation and experimental basis, ARHI, PTEN and WWOX is expected to become the treatment of serous ovarian cancer target genes. |
PDF Full Text Request